×

IPO-bound Aragen plans to spend 15 billion rupees over 3 years for expansion, MD says

By Thomson Reuters Nov 18, 2026 | 2:52 AM

By Rishika Sadam

HYDERABAD, Nov 18 (Reuters) – IPO-bound Aragen Life Sciences plans to invest about 15 billion rupees ($160.5 million) over three years to expand its drug ​development and manufacturing business, as the Indian firm ‌seeks to capture growing outsourcing demand from global pharmaceutical companies, a top executive said.

Diversification of supply chains beyond China and outsourcing of research and production have helped India’s contract drug market, estimated ‌at $9.3 ​billion by market research firm IMRAC, ⁠with companies such as ⁠Aragen, Syngene and Sai Life Sciences capturing rising demand.

Aragen expects to spend about 10 billion rupees on its contract development and manufacturing operations, while roughly 4 billion ​rupees will be invested in its discovery and contract research business, MD and CEO Manmahesh Kantipudi told ⁠Reuters in an interview last month.

The ⁠expansion comes as Aragen prepares for a ​stock market debut – comprising a fresh issue of 8 billion ​rupees and an offer for sale of up ‌to 27.3 million shares – and seeks to increase capacity across small molecules and complex biologics, areas it sees as key drivers of future growth.

Aragen helps pharmaceutical companies with ⁠the discovery, development and manufacture of drugs. The firm plans to expand its small-molecule manufacturing capacity to 650 kilolitres from 364 ⁠kilolitres, while biologics ‌manufacturing capacity is set to increase ⁠to 8.5 kilolitres by next year from ​2.5 kilolitres.

The ‌company, which has 591 customers, derives about ​65% of ⁠revenue from drug discovery services and the rest from development and manufacturing operations.

“We are going to leverage our customers for that growth,” Kantipudi said. “There’s a lot of headroom to grow (in CDMO).”

($1 = 93.4350 Indian rupees)

(Reporting by Rishika Sadam; Editing ​by Mrigank Dhaniwala)